# Reply to “Reconsidering dopaminergic modulation in Alzheimer's disease: A case for levodopa/carbidopa as a disease‐modifying agent”

**Authors:** Zsuzsa Sárkány, Joana Damásio, Sandra Macedo‐Ribeiro, Pedro M. Martins

PMC · DOI: 10.1002/alz.70533 · 2025-07-22

## Full-text entities

- **Diseases:** Alzheimer's disease (MESH:D000544)
- **Chemicals:** levodopa/carbidopa (MESH:C009265)

---
Source: https://tomesphere.com/paper/PMC12284310